Efficacy and safety of luspatercept in the treatment of myelodysplastic syndrome anemia：a single-group rate meta-analysis

LI Jiajing; WANG An’an; GUO Yuancheng; YU Xiaoda; GUO Jiangang; LIU Bei

doi:10.6039/j.issn.1001-0408.2025.09.20

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of luspatercept in the treatment of myelodysplastic syndrome anemia：a single-group rate meta-analysis

更新时间：2025-09-23

- Efficacy and safety of luspatercept in the treatment of myelodysplastic syndrome anemia：a single-group rate meta-analysis
- ZHONGGUO YAOFANG Vol. 36, Issue 9, Pages: 1135-1140(2025)
- 作者机构：
  
  1.兰州大学第一临床医学院，兰州　730000
  2.兰州大学第一医院血液内科，兰州　730000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.09.20
  CLC： R979.1
- Received：29 October 2024，
  
  Revised：2025-02-20，
  
  Accepted：21 February 2025，
  
  Published：15 May 2025
- 稿件说明：
移动端阅览
李佳璟,王安安,郭元成,等.罗特西普治疗骨髓增生异常综合征患者贫血的有效性与安全性的单组率Meta分析 [J].中国药房,2025,36(09):1135-1140.

LI Jiajing,WANG An’an,GUO Yuancheng,et al.Efficacy and safety of luspatercept in the treatment of myelodysplastic syndrome anemia：a single-group rate meta-analysis[J].ZHONGGUO YAOFANG,2025,36(09):1135-1140.
李佳璟,王安安,郭元成,等.罗特西普治疗骨髓增生异常综合征患者贫血的有效性与安全性的单组率Meta分析 [J].中国药房,2025,36(09):1135-1140. DOI： 10.6039/j.issn.1001-0408.2025.09.20.

LI Jiajing,WANG An’an,GUO Yuancheng,et al.Efficacy and safety of luspatercept in the treatment of myelodysplastic syndrome anemia：a single-group rate meta-analysis[J].ZHONGGUO YAOFANG,2025,36(09):1135-1140. DOI： 10.6039/j.issn.1001-0408.2025.09.20.

摘要

目的

分析罗特西普治疗骨髓增生异常综合征（MDS）患者贫血的有效性与安全性，为临床用药提供参考。

方法

计算机检索数据库PubMed、Cochrane Library、Embase、Web of Science中有关罗特西普治疗MDS患者贫血的文献，检索时限均为建库起至2024年1月。根据纳入与排除标准筛选文献后对其进行质量评价，采用RevMan 5.4软件进行单组率Meta分析与敏感性分析，并进行亚组分析。

结果

本研究纳入9篇文献，共756例患者。Meta分析

结果显示，使用罗特西普后，实现脱离红细胞输注≥8周的MDS患者比例为46%[95%CI（0.28，0.64），

＜0.000 01

]

，实现血液学改善-红系的患者比例为59%[95%CI（0.43，0.74），

＜0.000 01

]

。其中5篇文献报道了发生3～4级不良事件的MDS患者比例为14%[95%CI（0.07，0.22），

＝0.000 2

]

，一般情况不良、感染、血液及淋巴系统疾病是常见的不良事件。亚组分析结果显示，输血负担为实现脱离红细胞输注≥8周的患者比例的异质性来源，修订版国际预后评分系统（IPSS-R）分级、

SF3B1

基因突变和输血负担为实现血液学改善-红系的患者比例的异质性来源。敏感性分析结果显示，本研究结果稳定。

结论

罗特西普可显著改善MDS患者的输血依赖性，减轻输血负担，促进血液学改善；但应警惕其3～4级不良事件的发生，其中一般情况不良、感染、血液和淋巴系统疾病等较为常见。

Abstract

OBJECTIVE

To analyze the efficacy and safety of luspatercept in the treatment of myelodysplastic syndromes （MDS） anemia， and provide reference for clinical medication.

METHODS

The literature related to luspatercept for MDS anemia in PubMed， Cochrane Library， Embase and Web of Science were searched by computer， and the search time was from the establishment of the database to January 2024. The quality of literature was evaluated after they were screened according to inclusion and exclusion criteria， the single-group rate meta-analysis and sensitivity analysis were performed by using RevMan 5.4 software， and the subgroup analysis was conducted.

RESULTS

A total of 756 patients in 9 articles were included in this study. The results of meta-analysis showed that the proportion of MDS patients who reached ≥8 weeks of red blood cell transfusion independence （RBC-TI） was 46% after using luspatercept [95%CI （0.28， 0.64），

＜0.000 01

]

. The proportion of MDS patients whose hematological improvement in erythrocyte （HI-E） was 59% [95%CI （0.43， 0.74），

＜0.000 01

]

. Among them， 5 articles reported that the proportion of MDS patients with grade 3-4 adverse reactions was 14% [95%CI （0.07， 0.22），

＝0.000 2

]

， and the poor general condition， infection， blood and lymphatic system disease were the common adverse reactions. Subgroup anal

ysis showed that the source of heterogeneity was the blood transfusion burden in the proportion of MDS patients with RBC-TI≥8 weeks， and the source of heterogeneity was the revised international prognostic scoring system （IPSS-R） risk grade，

SF3B1

mutation status and blood transfusion burden in the proportion of MDS patients with HI-E. Sensitivity analysis showed that the results of this study were stable.

CONCLUSIONS

Luspatercept can significantly improve blood transfusion dependence， reduce blood transfusion burden and promote hematology improvement in MDS patients. But attention should be paid to the occurrence of grade 3-4 adverse events； adverse events such as poor general condition， infection， blood and lymphatic system diseases are more common.

关键词

Keywords

references

CAZZOLA M . Myelodysplastic syndromes [J ] . N Engl J Med ， 2020 ， 383 （ 14 ）： 1358 - 1374 .

SEKERES M A ， TAYLOR J . Diagnosis and treatment of myelodysplastic syndromes：a review [J ] . JAMA ， 2022 ， 328 （ 9 ）： 872 - 880 .

DAYYANI F ， CONLEY A P ， STROM S S ， et al . Cause of death in patients with lower-risk myelodysplastic syndrome [J ] . Cancer ， 2010 ， 116 （ 9 ）： 2174 - 2179 .

HENRY D H ， GLASPY J ， HARRUP R ， et al . Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome：open-label，dose-selection，lead-in stage of a phase 3 study [J ] . Am J Hematol ， 2022 ， 97 （ 2 ）： 174 - 184 .

GERMING U ， OLIVA E N ， HIWASE D ， et al . Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS：current and emerging strategies [J ] . Hemasphere ， 2019 ， 3 （ 6 ）： e314 .

FATTIZZO B ， VERSINO F ， BORTOLOTTI M ， et al . Luspatercept in combination with recombinant erythro-poietin in patients with myelodysplastic syndrome with ring sideroblasts：stimulating early and late-stage erythropoiesis [J ] . Eur J Haematol ， 2023 ， 110 （ 5 ）： 571 - 574 .

PALACIOS-BERRAQUERO M L ， ALFONSO-PIÉROLA A . Current therapy of the patients with MDS：walking towards personalized therapy [J ] . J Clin Med ， 2021 ， 10 （ 10 ）： 2107 .

HATZIMICHAEL E ， TIMOTHEATOU D ， KOUMPIS E ， et al . Luspatercept：a new tool for the treatment of anemia related to β-thalassemia，myelodysplastic syndromes and primary myelofibrosis [J ] . Diseases ， 2022 ， 10 （ 4 ）： 85 .

SCHMIERER B ， HILL C S . TGF-β-SMAD signal transduction：molecular specificity and functional flexibility [J ] . Nat Rev Mol Cell Biol ， 2007 ， 8 （ 12 ）： 970 - 982 .

FENAUX P ， HAASE D ， SANTINI V ， et al . Myelodysplastic syndromes：ESMO clinical practice guidelines for diagnosis，treatment and follow-up [J ] . Ann Oncol ， 2021 ， 32 （ 2 ）： 142 - 156 .

LOCATELLI F ， THOMPSON A A ， KWIATKOWSKI J L ， et al . Betibeglogene autotemcel gene therapy for non-β 0 /β 0 genotype β-thalassemia [J ] . N Engl J Med ， 2022 ， 386 （ 5 ）： 415 - 427 .

HIGGINS J P T ， THOMPSON S G ， DEEKS J J ， et al . Measuring inconsistency in meta-analyses [J ] . BMJ ， 2003 ， 327 （ 7414 ）： 557 - 560 .

PLATZBECKER U ， GERMING U ， GÖTZE K S ， et al . Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes （PACE-MDS）：a multicentre，open-label phase 2 dose-finding study with long-term extension study [J ] . Lancet Oncol ， 2017 ， 18 （ 10 ）： 1338 - 1347 .

FENAUX P ， PLATZBECKER U ， MUFTI G J ， et al . Luspatercept in patients with lower-risk myelodysplastic syndromes [J ] . N Engl J Med ， 2020 ， 382 （ 2 ）： 140 - 151 .

PLATZBECKER U ， DELLA PORTA M G ， SANTINI V ， et al . Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive，transfusion-dependent，lower-risk myelodysplastic syndromes （COMMANDS）：interim analysis of a phase 3，open-label，randomised controlled trial [J ] . Lancet ， 2023 ， 402 （ 10399 ）： 373 - 385 .

ZHANG Z X ， HU Q L ， TANG X D ， et al . Treatment of refractory or relapsed myelodysplastic neoplasms with luspatercept：a multicenter Chinese study [J ] . Ann Hematol ， 2023 ， 102 （ 11 ）： 3039 - 3047 .

FARRUKH F ， CHETRAM D ， AL-KALI A ， et al . Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts [J ] . Am J Hematol ， 2022 ， 97 （ 6 ）： E210 - E214 .

LANINO L ， RESTUCCIA F ， PEREGO A ， et al . Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts [J ] . Am J Hematol ， 2023 ， 98 （ 8 ）： E204 - E208 .

KOONS M ， SIGNORELLI J R ， BELL C ， et al . Real-world practices of luspatercept at an academic medical center [J ] . J Oncol Pharm Pract ， 2024 ， 30 （ 7 ）： 1173 - 1180 .

GONG Y ， HE G . Topic：As08-treatment/AS08i-observational studies：real world data confirms activity of luspatercept in higher risk and hypomethylating agents-failed patients with myelodysplastic syndromes [J ] . Leuk Res ， 2023 ， 128 ： 107275 .

MUKHERJEE S ， BROWN-BICKERSTAFF C ， MCBRIDE A ， et al . Real-world outcomes of patients with lower-risk myelodysplastic syndromes （LR-MDS） treated with luspatercept：an evaluation of US clinical practice utilization and treatment patterns [J ] . Blood ， 2022 ， 140 （ Suppl. 1 ）： 944 - 946 .

KOMROKJI R S ， AL ALI N ， BALL S ， et al . Luspatercept for treatment of lower risk myelodysplastic syndromes：real world data replicates medalist study results and confirms activity among hypomethylating agents and lenalidomide-treated patients [J ] . Blood ， 2022 ， 140 （ Suppl. 1 ）： 4039 - 4041 .

KOMROKJI R S ， AGUIRRE L E ， AL ALI N H ， et al . Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes [J ] . Blood Adv ， 2023 ， 7 （ 14 ）： 3677 - 3679 .

MALCOVATI L ， STEVENSON K ， PAPAEMMANUIL E ， et al . SF3B1-mutant MDS as a distinct disease subtype：a proposal from the International Working Group for the Prognosis of MDS [J ] . Blood ， 2020 ， 136 （ 2 ）： 157 - 170 .

GARZA A D L ， CAMERON R C ， GUPTA V ， et al . The splicing factor Sf3b1 regulates erythroid maturation and proliferation via TGF-β signaling in zebrafish [J ] . Blood Adv ， 2019 ， 3 （ 14 ）： 2093 - 2104 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Network meta-analysis of first-line treatment of metastatic colorectal cancer with different chemotherapy combination regimens

Improve effects of aromatase inhibitors on the height of children with short stature

Efficacy and safety of Compound danshen preparations combined with chemical drugs for peptic ulcer： a meta-analysis

Efficacy and safety of different treatments for moderate to severe Henoch-Schönlein purpura nephritis： a network meta-analysis

Efficacy and safety of amphotericin B combined with posaconazole in the treatment of cryptococcal meningitis complicated with AIDS

Related Author

ZHANG Xiaoqing

LIU Shuai

ZHANG Kai

JI Beibei

LUAN Wei

XIA Mengmeng

XIANG Jinbo

LUO Jun

Related Institution

Inner Mongolia Clinical Medical College， Inner Mongolia Medical University

Day-care Unit， Inner Mongolia Armed Police Hospital

Dept. of Medical Oncology， Inner Mongolia People’s Hospital

Dept. of Pediatrics， Renhe Hospital Affiliated to Three Gorges University

Dept. of Neonatology， Renhe Hospital Affiliated to Three Gorges University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰